Study of Semaglutide Injection for Treating Non-Diabetic Adults With Acute Ischemic Stroke A National, Phase 2, Randomized Trial Evaluating Safety and Effectiveness

What this Trial Is About

Researchers are evaluating the safety and effectiveness of Semaglutide in non-diabetic patients who have experienced an acute ischemic stroke. This type of stroke occurs when a blood clot blocks an artery in the brain, leading to brain cell damage or death. Even with current treatments that restore blood flow, many patients still face lasting disability. Semaglutide, a drug used for diabetes and obesity, has shown promise in animal studies for protecting brain cells during stroke, and this trial aims to see if it can improve outcomes in humans. Participants will be randomly assigned to one of two groups one receiving a weekly subcutaneous injection of 0.5 mg Semaglutide for four weeks plus standard stroke care, and the other receiving only the standard care according to national guidelines. The first dose of Semaglutide is given at the time of enrollment. The study compares these groups to assess whether Semaglutide reduces the impact of stroke beyond the usual treatments. Throughout the study, participants will be monitored for their functional recovery using the Modified Ranking Scale roughly three months after treatment. Researchers will also evaluate safety by tracking adverse events and mortality over the course of one year. Additional assessments include neurological improvement within 24 hours, changes in body weight and blood sugar levels, and recurrence of stroke or related events. The total observation period extends up to one year to gather comprehensive data on patient outcomes and safety.

Acute Subcutaneous SemaglutidE in Acute Ischemic sTroke